| Literature DB >> 28399336 |
Simon Andreasen1,2, Bita Esmaeli3, Sarah Linéa von Holstein4,5, Lauge Hjorth Mikkelsen5,6, Peter Kristian Rasmussen5,6, Steffen Heegaard5,6.
Abstract
Lacrimal gland tumors are rare and constitute a wide spectrum of different entities ranging from benign epithelial and lymphoid lesions to high-grade carcinomas, lymphomas, and sarcomas with large differences in prognosis and clinical management. The symptoms and findings of a lacrimal gland lesion are a growing mass at the site of the lacrimal gland, including displacement of the eyeball, decreased motility, diplopia, and ptosis. Pain is the cardinal symptom of an adenoid cystic carcinoma. Radiological findings characteristically include an oval, well-demarcated mass for benign lesions whereas malignant lesions typically display calcifications, destruction of bone, and invasion of adjacent structures. The diagnosis ultimately relies on histology, as does the choice of treatment and the prognosis. In recent years, the understanding of the biology of numerous types of lacrimal gland neoplasia has improved and the choice of treatment has changed accordingly and holds further promise for future targeted therapies. Treatment of benign epithelial lesions is surgical excision whereas carcinomas often require adjuvant radiotherapy and/or chemotherapy. In contrast, the cornerstone in management of lymphoid lesions is chemotherapy, often including a monoclonal antibody. This article presents an update on the clinical, radiological, histological, and molecular features, along with treatment strategies for tumors of the lacrimal gland. Copyright 2017 Asia-Pacific Academy of Ophthalmology.Entities:
Keywords: carcinoma; lacrimal gland; lymphoma; prognosis; treatment
Mesh:
Year: 2017 PMID: 28399336 DOI: 10.22608/APO.201707
Source DB: PubMed Journal: Asia Pac J Ophthalmol (Phila) ISSN: 2162-0989